Commentary on “Accounting for the Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trial”

By Liu Jen-pei  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 641-643

Taylor & Francis Ltd

Access to resources Recommend Favorite

Commentary on “Accounting for Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trial”

By Tsong Yi  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 639-640

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pediatric Safety of Tizanidine: Clinical Adverse Event Database and Retrospective Chart Assessment

By Henney Herbert R.  

Pediatric Drugs, Vol. 11, Iss. 6, 2009-12 ,pp. : 397-406

Adis International

Access to resources Recommend Favorite

Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study

By Kasliwal Rachna   Wilton Lynda V.   Shakir Saad A.W.  

Drug Safety, Vol. 32, Iss. 6, 2009-05 ,pp. : 499-507

Adis International

Access to resources Recommend Favorite

Safety and adverse event profile of duloxetine

By Wernicke Joachim F   Gahimer James   Yalcin Ilker   Wulster-Radcliffe Meghan   Viktrup Lars  

Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. : 987-993

Informa Healthcare

Access to resources Recommend Favorite